Monitoring of patients with concomitant diseases post coronavirus infection

This survey study presents data on the prevalence of, and the risk factors associated with post-COVID-19 complications for surviving patients with concomitant diseases during and after months of infection by coronavirus. A prospective, questionnaire-based study was conducted from May 2021 to June 2022. Patients who recovered from COVID-19 in 62 countries completed the online survey or did so during visits to hospitals and health centers. Individuals who recovered from COVID-19 were asked about their symptoms, adverse effects and adverse drug reactions. They were also asked if their concomitant diseases (diabetes, cardiovascular illness, asthma and GIT diseases) were affected after infection and if they had an uncontrolled treatment regimen. The severity of COVID was studied and the correlation coefficient to uncontrolled concomitant diseases was analyzed. Overall, 844 patients (44% female, 56% male) were assessed, and the highest percentage were suffering from long-term cough, dyspnea, constipation and uncontrolled concomitant diseases. A high significantly positive correlation between the severity of COVID infection and uncontrolled concomitant diseases was recorded. Many patients with mild to severe disease presentation reported persistent symptoms months later. Long-term complications to the lungs, heart, vascular system, kidneys, as well as metabolic disruption appear as uncontrolled treatment regimens for surviving COVID-19 patients.